Featured Publications
Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
Yildirim I, Lapidot R, Shaik-Dasthagirisaheb Y, Hinderstein S, Lee H, Klevens M, Grant L, Arguedas Mohs A, Cane A, Madoff L, Johnson H, Ivanof C, Burns M, Pelton S. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. Pediatrics 2023, 153 PMID: 38087952, DOI: 10.1542/peds.2023-063039.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD casesPCV13 eraPneumococcal diseaseCases of IPDIncidence of IPDRates of IPDPneumococcal conjugate vaccine useSerotype 15B/CImplementation of PCV13Non-PCV13 serotypesPneumococcal conjugate vaccineConfidence intervalsStatewide surveillance systemIPD incidence ratesIPD ratesPenicillin nonsusceptibilityConjugate vaccineVaccine serotypesSerotype 19ASterile sitesIncidence rateVaccine useLower incidenceVaccine formulations
2021
Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination
Adamkiewicz T, Thomas S, Tunali A, Lai K, Yee M, Yildirim I, Lane P, Omole F, Farley M. Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination. Blood 2021, 138: 763. DOI: 10.1182/blood-2021-154474.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseSickle cell diseaseIPD ratesPCV periodPCV7 licensureMean ageRelative riskCell diseaseGeneral populationNew vaccinesNon-PCV13 serotypesPneumococcal polysaccharide vaccineRegistry of patientsPopulation-based surveillanceProphylactic antibiotic useEmory University Institutional Review BoardAntibiotic susceptibility testingInstitutional review boardUniversity Institutional Review BoardAge of infectionIPD diagnosisPCV eraPCV13 periodPCV13 serotypesPCV7 period